Rydex Inverse 2x S&P Select Sector Hlth (RHO) News
Follow Rydex Inverse 2x S&P Select Sector Hlth (RHO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 67 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Roche Puts Future Germany Investment Decisions on Hold
Roche’s Germany chief said the company has put all future investment decisions in Germany on hold for the time being, citing healthcare cost-cutting policies.
EQUITY | Oct 19, 2026, 08:11 AM UTC
M
Biocon Settles Roche's US Patent Lawsuit Over Proposed Breast-Cancer Biosimilar
Biocon said it settled Genentech's US lawsuit over its proposed biosimilar of the breast-cancer drug Perjeta.
EQUITY | Oct 14, 2026, 06:56 PM UTC
M
Roche Licenses Rona Obesity Therapy in Deal Worth Up to $1.2 Billion
Roche struck a deal with China's Rona Therapeutics for worldwide rights to an experimental therapy for obesity and metabolic diseases, with payments of up to $1.16 billion.
MNA | Oct 13, 2026, 12:43 PM UTC
M
Roche Strikes Obesity Drug Licensing Deal Worth Up to $1.16 Billion
Roche entered a licensing agreement with Rona Therapeutics for its investigational obesity drug candidate, worth up to $1.16 billion, the Chinese biotech firm said Tuesday.
MNA | Oct 13, 2026, 08:14 AM UTC
M
Roche Licenses Parkinson's Therapy From Alector For Up To $1.27B
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's disease treatment. Alector will receive $100 million upfront and potential future payments.
EQUITY | Oct 05, 2026, 12:06 PM UTC
M
Roche Stock Rises on AI-Driven Lab Plans
Roche Holding (RHHBY) announced plans for autonomous, AI-driven research laboratories. The company's U.S.-dollar share quote was $52.22 on October 1, 2026, which is 26.62% above the GF Value estimate.
EQUITY | Oct 02, 2026, 12:08 AM UTC
H
Genentech Phase III Combo Cuts PFS Risk 44%
Genentech's Phase III evERA trial showed giredestrant plus everolimus improved progression-free survival (PFS) by 44% versus standard endocrine therapy plus everolimus in the intent-to-treat population. The FDA has accep
EQUITY | Oct 01, 2026, 05:00 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Key facts: Roche (RO) fenebrutinib NDA; backs CHF600M giredestrant
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
NEWS | Sep 30, 2026, 07:02 AM UTC
L
Roche Says FDA Accepts Roche NDA For Fenebrutinib Under Priority Review
ROCHE HOLDING AG BX:RHO
REGULATION | Sep 30, 2026, 05:05 AM UTC
L
Roche (RHO) Wins FDA Priority Review for Fenebrutinib in RMS and PPMS
Roche said the FDA accepted its NDA under priority review for fenebrutinib, a BTK inhibitor for relapsing and primary progressive multiple sclerosis, supported by three Phase III studies.Material DetailsContext by AI Ana
REGULATION | Sep 30, 2026, 05:01 AM UTC
L
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fene
REGULATION | Sep 30, 2026, 05:01 AM UTC
L
Roche (RHO) Launches CE-Marked Newborn Screening Kit
Roche launched the LightMix Newborn TREC/SMN1/HBB kit, a CE-marked test that screens newborns for SMA, SCID and SCD on LightCycler systems in countries accepting the CE mark.Material DetailsContext by AI AnalystThis exte
NEWS | Sep 30, 2026, 05:01 AM UTC
L
Genentech, Inc. Gets FDA Priority Review for Fenebrutinib in RMS and PPMS
Genentech said the FDA accepted its NDA under priority review for fenebrutinib, a BTK inhibitor for relapsing and primary progressive multiple sclerosis, supported by three Phase III studies.Material DetailsContext by AI
REGULATION | Sep 30, 2026, 05:01 AM UTC
L
Roche Shows New Research-And-Development Approach Is Bearing Fruit — Market Talk
Roche Holding's clinical-trial success rate has improved and research-and-development cycles shortened since the company introduced a more stringent approach to its drug pipeline after a series of failed studies in 2022,
CENTRAL_BANK | Sep 29, 2026, 01:36 PM UTC
H
Roche Dashes Hopes of Guidance Upgrade — Market Talk
Roche Holding struck an upbeat tone on its drug pipeline, but didn't deliver the guidance upgrade some expected, as it gave investors an update on its pharma business, RBC Capital Markets analysts say in a research note.
NEWS | Sep 29, 2026, 12:55 PM UTC
L
Roche Needs Next Drug Launches to Go Smoothly — Market Talk
Roche Holding shares trade at a premium to those of peers, which will be difficult to justify if the launches of its next drugs don't deliver on expectations, Jefferies analysts say in a research note. There were no big
EQUITY | Sep 29, 2026, 12:35 PM UTC
L
Roche Signals It Is Too Soon to Know if AI Improves Trial Success Rates — Market Talk
Roche Holding's research and early development is becoming more productive thanks to the integration of AI into its workflows, but it is too soon to know if the technology improves a drug candidate's chances in a clinica
NEWS | Sep 29, 2026, 12:23 PM UTC
L
Roche Seems Increasingly Confident in Obesity Portfolio — Market Talk
Roche Holding's confidence in its portfolio of medicines for obesity and diabetes seems to be growing as the Swiss drugmaker seeks an expansion into broader cardiovascular indications, UBS analysts say in a research note
NEWS | Sep 29, 2026, 12:14 PM UTC
L
Biotech Stocks Facing FDA Decision In October 2026
SOUTH SAN FRANCISCO (dpa-AFX) - The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.As we turn to October, here's a recap of some of the regulatory developments
REGULATION | Sep 29, 2026, 09:48 AM UTC
L
Genentech Starts $750M Hillsboro Expansion, Operations Planned in 2031
Genentech broke ground on a $750M expansion of its Hillsboro, OR manufacturing site, doubling its size and adding device fill-finish and combination product capabilities. Commercial operations are planned to begin in 203
NEWS | Sep 28, 2026, 10:00 PM UTC
L
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
Genentech, a member of the Roche Group (SIX:RO, ROP; OTC:RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity
NEWS | Sep 28, 2026, 10:00 PM UTC
L
Roche Has Room for More Deals, CFO Says — Market Talk
Roche Holding has financial room for more deals, CFO Alan Hippe tells investors at a company event in London. The Swiss drugmaker deployed 18.2 billion Swiss francs to deals between 2022 and 2025, and its net debt remain
NEWS | Sep 28, 2026, 01:41 PM UTC
L
Roche Halts Development of Obesity Drug Candidate
By Adria CalatayudRoche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets.The Swiss drugmaker said it returned rights to th
NEWS | Sep 28, 2026, 12:34 PM UTC
L
Roche outlines plans to move towards autonomous AI labs
Swiss pharmaceutical giant Roche BX:RHO outlined plans to move towards autonomous AI labs to speed up research and development discovery at its pharma investor day on Monday.Roche is committed to "AI independence" in R&D
NEWS | Sep 28, 2026, 11:02 AM UTC
L
Weekly Recap: sefaxersen UPCR cut wk37 and enicepatide cuts HbA1c, weight
Roche Holding Ltd (SIX:RO) posted a string of clinical and regulatory wins: Phase III IMAgINATION showed sefaxersen cut UPCR, Phase II enicepatide met diabetes and weight endpoints, the EC approved Susvimo with Contivue
NEWS | Sep 28, 2026, 05:01 AM UTC
L
Roche, Atavistik Bio sign drug-discovery deal worth up to $2 billion
By Kunal DasAtavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche BX:RHO potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney a
NEWS | Sep 24, 2026, 02:28 PM UTC
L
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche BX:RHO potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidne
NEWS | Sep 24, 2026, 11:59 AM UTC
L
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. deposi
NEWS | Sep 23, 2026, 06:11 PM UTC
L
Roche to Move Quickly Toward Filing for Approval of New Autoimmune Drug — Market Talk
Roche Holding is expected to move quickly to file for an accelerated approval for its sefaxersen drug candidate, a direct competitor to Novartis's Fabhalta, RBC Capital Markets analysts say. The Swiss drugmaker reported
NEWS | Sep 23, 2026, 02:18 PM UTC
L
Roche Is Becoming More Productive — Market Talk
Roche Holding is showing signs of improving its research-and-development productivity, Berenberg analysts say in a research note. The returns on the Swiss drugmaker's research-and-development investments this year are on
NEWS | Sep 23, 2026, 12:45 PM UTC
L
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
By Adria CalatayudRoche Holding said a drug candidate for an autoimmune disease known as IgA nephropathy met the primary goal of a late-stage clinical study, paving the way for the company to seek regulatory approval.The
NEWS | Sep 23, 2026, 05:35 AM UTC
L
Roche (RHO) Reports Phase III Interim Win in IgAN
Roche said Phase III IMAgINATION met its primary endpoint, with once-monthly sefaxersen showing statistically significant proteinuria reduction vs placebo at week 37 in adults with IgA nephropathy. Safety was consistent
NEWS | Sep 23, 2026, 05:22 AM UTC
L
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primar
NEWS | Sep 23, 2026, 05:21 AM UTC
L
Roche Posts Interim Data Regarding Sefaxersen
ROCHE HOLDING AG BX:RHO
NEWS | Sep 23, 2026, 05:19 AM UTC
L
Roche proposes former Takeda CEO for board seat
Roche BX:RHO on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals TSE:4502, for election to the Swiss company's board of directors at its AGM next March."Christophe's intimate know
NEWS | Sep 23, 2026, 05:09 AM UTC
L
Roche Board Proposes Christophe Weber For Election To Board
ROCHE HOLDING AG BX:RHO
NEWS | Sep 23, 2026, 05:03 AM UTC
L
Roche Holding Ltd (RHO) To Propose Christophe Weber for Board Seat
Roche Holding Ltd said its Board will propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at its March 9, 2027 AGM.Material DetailsContext by AI AnalystThis is an early governanc
NEWS | Sep 23, 2026, 05:03 AM UTC
L
Roche: To Propose Weber Appointment to Board at AGM on March 9, 2027
Roche: To Propose Weber Appointment to Board at AGM on March 9, 2027
NEWS | Sep 23, 2026, 05:03 AM UTC
L
Change in Roche’s Board of Directors
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General
NEWS | Sep 23, 2026, 05:02 AM UTC
L
Roche: Weber Is Former CEO of Takeda Pharmaceuticals
Roche: Weber Is Former CEO of Takeda Pharmaceuticals
NEWS | Sep 23, 2026, 05:02 AM UTC
L
Roche to Propose Christophe Weber as New Board Member
Roche to Propose Christophe Weber as New Board Member
NEWS | Sep 23, 2026, 05:01 AM UTC
L
Genentech Reports Positive Phase III Interim for Sefaxersen in IgAN
Genentech said Phase III IMAgINATION met its primary endpoint, with sefaxersen significantly reducing proteinuria vs placebo at 37 weeks in IgA nephropathy. Safety was consistent with prior data; the blinded study contin
NEWS | Sep 23, 2026, 05:00 AM UTC
L
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with
NEWS | Sep 23, 2026, 05:00 AM UTC
M
Roche obesity drug trial met main goals on glucose and weight
Roche Holding said its obesity drug candidate met the main objectives of a midstage clinical trial, helping patients reduce blood glucose and body weight, as it looks to enter the weight-loss drug market dominated by Eli
EQUITY | Sep 22, 2026, 03:28 PM UTC
M
Celldex drug meets goals in two late-stage trials
Celldex Therapeutics said its experimental drug for a skin disease met the main and secondary goals in two late-stage trials.
EQUITY | Sep 22, 2026, 11:38 AM UTC
M
Roche obesity drug shows blood sugar control and 15.5% weight loss
Roche said its experimental dual-acting obesity drug improved blood sugar control and drove an average 15.5% body-weight loss in a mid-stage trial in overweight or obese patients with type 2 diabetes.
EQUITY | Sep 22, 2026, 11:22 AM UTC
M
Roche’s enicepatide helps patients with type 2 diabetes lose weight
Roche said its experimental obesity drug enicepatide helped patients with type 2 diabetes lose weight and lower blood sugar in a mid-stage clinical trial.
EQUITY | Sep 22, 2026, 08:31 AM UTC
M
Roche obesity drug enicepatide trial shows positive results
Roche Holding reported positive results for enicepatide in adults with diabetes and obesity, according to Vontobel’s Stefan Schneider, building on prior efficacy data in obese patients without diabetes.
EQUITY | Sep 22, 2026, 06:50 AM UTC
M
Roche reports positive Phase II topline data for enicepatide
Roche said it has positive topline results from CT-388-104, a Phase II trial of once-weekly enicepatide (CT-388), a dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity.
EQUITY | Sep 22, 2026, 05:05 AM UTC
M
Roche’s Susvimo approved by European Commission for use in Europe
Roche said the European Commission approved Susvimo, its neovascular age-related macular degeneration treatment, for use in Europe based on data from three clinical studies.
REGULATION | Sep 21, 2026, 04:10 PM UTC
M
European Commission approves Roche’s Susvimo® for nAMD treatment
Roche says the European Commission approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for neovascular age-related macular degeneration (nAMD).
REGULATION | Sep 21, 2026, 03:51 PM UTC
M
CHMP recommends EU approval of Roche’s Ocrevus for children
CHMP has recommended EU approval of Roche’s Ocrevus for children and adolescents.
REGULATION | Sep 18, 2026, 10:46 AM UTC
M
Roche Says Phase III Celestimo Study Hits Primary Endpoint
Roche said its Phase III Celestimo study met the primary endpoint in follicular lymphoma.
EQUITY | Sep 17, 2026, 05:07 AM UTC
M
Roche says CELESTIMO phase III met primary endpoint
Roche said its phase III CELESTIMO study met its primary endpoint, with Lunsumio plus lenalidomide improving progression-free survival versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma. Overal
EARNINGS | Sep 17, 2026, 05:03 AM UTC
M
Roche says Lunsumio plus lenalidomide improves PFS in CELESTIMO
Roche announced phase III CELESTIMO results for Lunsumio (mosunetuzumab) plus lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide in relapsed or refractory follicular lymphoma.
EARNINGS | Sep 17, 2026, 05:01 AM UTC
M
Genentech Phase III CELESTIMO shows Lunsumio regimen improves PFS
Genentech said its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met the primary endpoint with statistically significant, clinically meaningful PFS improvement versus Rituxan plus lenalidomide in relapsed/refra
EARNINGS | Sep 17, 2026, 05:00 AM UTC
M
Genentech reports Phase III CELESTIMO PFS improvement for Lunsumio
Genentech says its Phase III CELESTIMO study of Lunsumio (mosunetuzumab-axgb) plus lenalidomide vs Rituxan (rituximab) plus lenalidomide in relapsed/refractory follicular lymphoma showed significantly improved progressio
EARNINGS | Sep 17, 2026, 05:00 AM UTC
L
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelite
NEWS | Sep 13, 2026, 12:01 AM UTC
M
FDA grants priority review for Roche’s Enspryng for Mogad
Roche Holding AG received a U.S. FDA priority review for its Enspryng for Mogad, according to the report.
REGULATION | Sep 10, 2026, 05:04 AM UTC